Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 22.4% from a year ago
Net receivables stood at $121M at the end of Q1 FY2026, up 22.4% from a year earlier and down 23.9% from the prior quarter. Over 3 fiscal years it compounded at +57.8% a year.
Context
- Net receivables amounted to 9.3% of total assets at the end of Q1 FY2026, up 1.8 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +22.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 159M USD
- Year-over-year change
- +30.5%
- 4-year CAGR
- +37.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 159M | +30.5% |
| FY2024 | 2024-12-31 | 121.8M | +66.0% |
| FY2023 | 2023-12-31 | 73.39M | +81.5% |
| FY2022 | 2022-12-31 | 40.45M | -9.0% |
| FY2021 | 2021-12-31 | 44.43M | — |
Net Receivables vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's Mar 2026 net receivables of $121M is the 4th highest of the 11 companies compared; the peer median is $8.82M.
- Its year-over-year change of +22.4% is the 6th highest of 9, against a peer median of +136.2%.
- Net receivables amounts to 9.3% of total assets for RARE, versus a peer median of 4.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.08T | +136101.6% | +25.3% | 9.3% | |
| Jun 2026 | $254.48M | +231.1% | +101.4% | 20.9% | |
| Jun 2026 | $239.04M | +21.9% | +5.3% | 7.4% | |
| Mar 2026 | $121M | +22.4% | +57.8% | 9.3% | |
| Mar 2026 | $17.96M | +243.7% | -14.3% | 7.3% | |
| Mar 2026 | $10.94M | -42.9% | -3.3% | 3.2% | |
| Mar 2026 | $6.71M | +314.9% | +229.3% | 3.4% | |
| Mar 2026 | $3.56M | +41.2% | -61.5% | 0.5% | |
| Mar 2026 | $1.88M | -21.6% | — | 4.6% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RARE) | $8.82M | +136.2% | +5.3% | 4.0% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 307.58M | 132.94M | 213.58M | 173.73M | 434M |
| Short-term Investments | 432.61M | 614.82M | 363.63M | 436.3M | 259M |
| Net Receivables | 44.43M | 40.45M | 73.39M | 121.8M | 159M |
| Inventory | 16.23M | 26.77M | 33.97M | 45.01M | 52M |
| Other Current Assets | 55.75M | 68.93M | 47.62M | 40.29M | 47M |
| Total Current Assets | 856.6M | 883.9M | 732.18M | 817.12M | 951M |
| Property, Plant & Equipment (Net) | 176.18M | 259.73M | 290.57M | 265.93M | 267M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44M |
| Intangible Assets | 130.79M | 160.11M | 166.27M | 178.31M | 176M |
| Long-term Investments | 293.86M | 148.97M | 199.9M | 135M | 59M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.56M | 48.34M | 57.69M | 62.68M | 35M |
| Total Non-current Assets | 665.79M | 661.55M | 758.83M | 686.33M | 581M |
| Total Assets | 1.52B | 1.55B | 1.49B | 1.5B | 1.53B |
| Account Payables | 17.14M | 43.27M | 42.11M | 38.76M | 31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 81M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.61M | 1.48M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 142.79M | 87.47M | 183M |
| Total Current Liabilities | 181.37M | 261.21M | 280.44M | 344.15M | 384M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.17B |
| Deferred Tax Liabilities | 33.31M | 31.67M | 30.06M | 30.06M | 30M |
| Deferred Revenue (Non-current) | 1.47M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 352.79M | 880.26M | 874.53M | 836.91M | (4M) |
| Total Non-current Liabilities | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B |
| Total Liabilities | 599.84M | 1.19B | 1.22B | 1.24B | 1.61B |
| Common Stock | 69K | 70K | 82K | 92K | 0 |
| Retained Earnings | (2.07B) | (2.78B) | (3.39B) | (3.96B) | (4.53B) |
| Accumulated OCI | (1.4M) | (6.57M) | 647K | (643K) | 1M |
| Other Stockholders Equity | 0 | 0 | 432K | 3.59M | 8M |
| Minority Interest | 0 | 0 | 0 | 7M | 7M |
| Total Equity | 922.56M | 352.49M | 275.41M | 262.3M | (73M) |
| Total Debt | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B |
| Net Debt | (265.61M) | (101.35M) | (170.42M) | (133.39M) | 842M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.